A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Ibrutinib (Primary) ; Ixazomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Aug 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2018 to 13 Aug 2018.
- 14 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.